Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty to reduce the need for intraoperative and postoperative blood transfusions. Limited research is available on its use in hip fracture patients. We hypothesize that the use of TXA preoperatively, perioperatively, and postoperatively will decrease blood loss and need for blood transfusion postoperatively.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gregory Georgiadis; Gregory M Georgiadis MD
• Treatments: Pharmaceutical Solutions; Tranexamic Acid

Criteria

Inclusion Criteria:

• Over the age of 60 years

• Hip fracture requiring surgical intervention

• Signs consent and agrees to participate

Exclusion Criteria:

• Under the age of 60

• Does not sign consent or refuses participation

• Known hypersensitivity to tranexamic acid

• Multiple acute fractures

• Creatinine clearance <30

• History of seizures

• Active hormone therapy

• History of coagulation abnormality

• History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last year or history or recurrent DVT/PE

• Myocardial infarction (MI) and/or stents within the past year

• History of intracranial hemorrhage

• Acquired defective color vision

• Patients admitted directly to nursing units or surgery without stay in the Emergency Center

• Patients who sustain fracture while hospitalized at ProMedica Toledo Hospital